Download Report

UCB 2014 Full-year
Financial Results
London, 27 February 2015
Anna, living with epilepsy
2
Disclaimer and safe harbor
Forward-looking statements:
This presentation contains forward-looking statements based on current plans, estimates and beliefs of management. All
statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including
estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, political,
regulatory or clinical results and other such estimates and results. By their nature, such forward-looking statements are not
guarantees of future performance and are subject to risks, uncertainties and assumptions which could cause actual results to
differ materially from those that may be implied by such forward-looking statements contained in this presentation. Important
factors that could result in such differences include: changes in general economic, business and competitive conditions, the
inability to obtain necessary regulatory approvals or to obtain them on acceptable terms, costs associated with research and
development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial
decisions or governmental investigations, product liability claims, challenges to patent protection for products or product
candidates, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration
of such laws and hiring and retention of its employees. Additionally, information contained in this document shall not constitute an
offer to sell or the solicitation of an offer to buy any securities, nor shall there be any offer, solicitation or sale of securities in any
jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities
laws of such jurisdiction. UCB is providing this information as of the date of this presentation and expressly disclaims any duty to
update any information contained in this presentation, either to confirm the actual results or to report a change in its expectations.
There is no guarantee that new product candidates in the pipeline will progress to product approval or that new indications for
existing products will be developed and approved. Products or potential products which are the subject of partnerships, joint
ventures or licensing collaborations may be subject to differences between the partners. Also, UCB or others could discover
safety, side effects or manufacturing problems with its products after they are marketed.
Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment
and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and
reimbursement.
3
UCB FY 2014 information flow
‫ ן‬UCB in an evolving strategic context
• Jean-Christophe Tellier, CEO
‫ ן‬Core products, Cimzia , Vimpat , Neupro
®
®
®
+ Keppra®, reach 73% of net sales
• Jean-Christophe Tellier, CEO
‫ ן‬Topline growth paired with strict cost management
• Detlef Thielgen, CFO
‫ ן‬Next wave of new potential solutions for patients advances
• Iris Löw-Friedrich, CMO
‫ ן‬Potential breakthrough passed first decision point
• Ismail Kola, CSO
‫ ן‬Conclusion
• Jean-Christophe Tellier, CEO
‫ ן‬Q&A
UCB in an evolving
strategic context
Jean-Christophe Tellier, CEO
Nuria, living with lupus
5
UCB adresses the evolution of the healthcare ecosystem
Active,
„digital“
Patients
Healthcare
costs:
Sustainable?
Shift to
patients
Patient
Competition
from within
and outside
Expanding
and Aging
Population
Solutions
Holistic
approach
UCB to become the
patient preferred
biopharma company
6
UCB’s value proposition: The patient preferred biopharma
Impact patients’ lives across the value chain by translating
superior insights into patient value
Patients
Shareholder
value
Patient
value
Solutions
Sciences
7
At UCB: 4 Pillars to drive Patient Value
NewMedicines
Development/
Medical Practices
Neurology
Immunology
Patient
Value
Units
Patient
Value
Practices
Marketing Practices
Bone
Established
Brands
Patient
Value
Operations
Patient
Value
Functions
Talent
Legal
Technical
Operations
Finance
8
UCB’s strategic growth priorities
Continuing our growth path
Grow Cimzia®, Vimpat® and Neupro®
Advance and prepare launch of next wave
Patient
value
Deliver breakthrough solutions
Competitive 30% rEBITDA margin in 2018
Constantly ensure quality and compliance
Engaged colleagues, patients and business partners
Core products,
Cimzia®, Vimpat®,
Neupro® + Keppra®,
reach 73% of net sales
Jean-Christophe Tellier, CEO
Hüseyin, living with rheumatoid arthritis
10
Cimzia® performance
Reaching more patients
€ million
FY 2014
FY 2013
Actual
CER
North America
503
379
33%
33%
Europe
232
168
39%
39%
Japan
29
20
50%
62%
6
6
3%
12%
27
22
23%
26%
797
594
34%
35%
Emerging markets1
Rest of the World
Total Cimzia®
Cimzia®
global
sales
North
America
Europe
Japan
1 Brazil, Russia, India, China, Mexico and Turkey
Cimzia® available to patients in 48 countries, including Brazil, Russia, Mexico & Turkey
Numbers may not add due to rounding
11
Cimzia® in-market performance (December 2014)
25%
U.S. - Cimzia® Rheumatology – R3M TRx Share
US - Cimzia® Rheumatology Growth
4.2%
20%
•
In-Market growth and share
based on TRx
3.8%
•
Shares calculated based on
Anti-TNF market
3.6%
•
In-market growth is calculated
for MAT Dec'14 vs. MAT Dec’'13
•
Market share is calculated for
R3M Dec'14 and market share
growth is shown against R3M
Dec'13
•
In-Market growth and share
based on Exit Patients
•
Shares calculated based on
RA Anti-TNF market
•
In-market growth is calculated
for Dec’14 vs. Dec’'13
•
Market share is calculated for
R3M Dec'14 and market share
growth is shown against R3M
Dec'13
4.0%
TRx market
share : 4.1%
+0.6%
15%
19.1%
10%
3.4%
5%
5.4%
7.5%
3.2%
0%
Anti-TNF
45%
All Biologics
Cimzia
EU - Cimzia RA Growth
30%
25%
Jun'14
Aug'14
Oct'14
Dec'14
EU - Cimzia RA – R3M Patient Share
Patient market
share : 10.4%
+2.5%
10.0%
38.6%
9.5%
9.0%
20%
15%
8.5%
18.3%
10%
5%
Apr'14
10.5%
40%
35%
3.0%
Dec'13 Feb'14
8.0%
9.1%
0%
Anti-TNF
All Biologics
Cimzia
7.5%
Dec'13
Feb'14
Apr'14
Jun'14
Aug'14
Oct'14
Dec'14
12
Cimzia®: access for patients in the U.S.
*62% of insured lives covered without restrictions
Covered lives in millions
143
150
159
163
122
125
114
118
29
32
37
38
Jan-12
Jan-13
Jan-14
Jul-14
preferred
173*
124
49
Jan-15
co-preferred
Total lives with Cimzia® (certolizumab pegol) in the U.S.
Source: Preferred lives from UCB Internal Contracts Database, Co-preferred from UCB internal analysis.
13
Vimpat® performance
Reaching more patients
€ million
FY 2014
FY 2013
Actual
CER
North America
344
314
9%
9%
Europe
112
87
28%
28%
6
4
50%
60%
10
6
80%
86%
471
411
15%
15%
Emerging markets1
Rest of the World
Total Vimpat®
Vimpat®
global
sales
North
America
Europe
1 Brazil, Russia, India, China, Mexico and Turkey
2 Partial-onset seizures
3 Primary general tonic clonic seizures
Vimpat® available to patients in 43 countries, including Russia, India & Mexico
14
Vimpat® in-market performance (December 2014)
US - Vimpat Growth
20%
US – Vimpat – R3M TRx Share
3.5%
18%
16%
3.3%
14%
TRx market
Share : 3.3%
+0.4%
12%
U.S.
10%
18.0%
3.1%
2.9%
8%
6%
•
In-Market growth and
share based on TRx
•
In-market growth is
calculated for MAT Dec’14
vs. MAT Dec'13
•
Market share is calculated
for R3M Dec'14 and market
share growth is shown
against R3M Dec'13
2.7%
4%
4.6%
2%
0%
Market
30%
Vimpat
2.5%
Dec'13
Feb'14
EU - Vimpat Growth
Apr'14
Jun'14
Aug'14
Oct'14
Dec'14
EU – Vimpat – R3M TDx Share
2.5%
25%
20%
15%
TDx market
share : 2.2%
+0.4%
22.2%
10%
5%
2.3%
•
In-Market growth and share
based on TDx
2.1%
•
In-market growth is calculated
for MAT Dec'14 vs. MAT Dec'13
1.9%
•
Market share is calculated for
R3M Dec'14 and market share
growth is shown against R3M
Dec'13
1.7%
-2.9%
0%
Market
-5%
Vimpat
1.5%
Dec'13
Feb'14
Apr'14
Jun'14
Aug'14
Oct'14
Dec'14
15
Neupro® performance
On-going performance
€ million
FY 2014
FY 2013
Actual
CER
39
40
-3%
-3%
Europe
138
129
7%
7%
Japan
16
9
89%
89%
Emerging markets1
2
2
-1%
5%
Rest of the World
5
3
58%
60%
200
182
10%
10%
North America
Total Neupro®
Neupro®
global
sales
Europe
North
America
Japan
1 Brazil, Russia, India, China, Mexico and Turkey
Neupro® available in 44 countries, including Russia & Mexico
Numbers may not add due to rounding
16
Neupro® in-market performance (December 2014)
8.0%
Neupro PD Growth
US – Neupro PD – R3M TRx Share
7.0%
6.0%
TRx market
share : 6.6%
+0.3%
5.0%
U.S.
4.0%
6.5%
3.0%
2.0%
1.0%
0.4%
0.4%
Market
Competitors
0.0%
7.0%
6.9%
6.8%
6.7%
6.6%
6.5%
6.4%
6.3%
6.2%
6.1%
6.0%
Dec'13
Feb'14
Apr'14
Jun'14
Aug'14
Oct'14
•
In-market growth and share
based on TRx
•
Shares calculated based on PD
and RLS Key Competitors
markets
•
In-market growth is calculated for
Current R6M vs. Previous R6M
•
In-market share is calculated for
R3M Dec'14 and market share
growth is shown against R3M
June’14
Dec'14
Neupro
EU Neupro PD Growth
EU – Neupro PD – R3M TDx Share
10%
16.0%
8%
6%
TDx market
shares : 15.6%
+1.4%
15.5%
15.0%
1.2%
14.5%
-0.9%
0%
Market
-2%
Competitors
In-market growth and share based
on TDx
•
Shares calculated based on PD and
RLS Key Competitors markets
•
In-market growth is calculated for
MAT Dec'14 vs. MAT Dec'13
•
Market share is calculated for R3M
Dec'14 and market share growth is
shown against R3M Dec'13
8.3%
4%
2%
•
Neupro
14.0%
Dec'13
Feb'14
Apr'14
Jun'14
Aug'14
Oct'14
Dec'14
17
Growth drivers
Core medicines tracking well towards peak sales target of
€ 3.1 billion
CVN combined
* By the end of this decade
2014 net sales
Expected peak sales*
at least
€ 797 million
€ 1.5 billion
€ 471 million
€ 1.2 billion
€ 200 million
€ 400 million
€ 1 468 million
€ 3.1 billion
18
Keppra® performance
Sizeable franchise
€ million
FY 2014
FY 2013
Actual
CER
North America
204
223
-9%
-9%
Europe
269
315
-15%
-15%
Japan
64
62
3%
12%
Emerging markets1
91
71
28%
34%
Rest of the World
37
40
-7%
-8%
665
712
-7%
-5%
Total Keppra®
E Keppra® now approved for
monotherapy in Japan! (Feb. 2015)
Status of exclusivity:
• Keppra® in Japan - exclusivity until
2018
• U.S. - expired November 2008
(Keppra® XR - September 2011)
• Europe - expired September 2010
1 Brazil, Russia, India, China, Mexico and Turkey
Numbers may not add due to rounding
Keppra®
global
sales
Europe
North
America
Topline growth
paired with strict
cost management
Detlef Thielgen, CFO
Philip, living with axial spondyloarthritis
20
UCB FY 2014 financial highlights
Top-line performance driving earnings growth
KU treated as discontinued asset*
Actual
CER
+7%
+8%
€ 1 912 million
+2%
+3%
Recurring EBITDA
€ 609 million
+14%
+17%
Net profit of the Group
€ 199 million
+37%
+51%
€ 1.69
+37%
+46%
Revenue
•
Continued net sales growth of core medicines
Total operating expenses
•
•
•
•
€ 3 344 million
Overall OpEx ratio improved:
S, G & A -2%
R&D expense +5%, stable at 28% of revenue
Higher revenue and strict cost management
Core earnings per share
(Based on 191 million weighted average shares outstanding)
EBITDA: Earning before interests, taxes, depreciation and amortization charges
CER: Constant Exchange Rate
* 2013 figures restated
21
Geographic and therapeutic breakdown
FY 2014 net sales : € 2 938 million, +5%
Europe
39%; +3%
+12%
22
Recurring EBITDA
Topline growth paired with strict cost management
€ million
FY 2014
FY 2013
Actual
(restated)1
Variance
Actual
CER
3 344
3 133
7%
8%
2 938
2 795
5%
6%
Royalty income and fees
163
171
-5%
-7%
Other revenue
243
167
45%
45%
2 291
2 168
6%
7%
Marketing and selling expenses
-779
-793
2%
1%
R&D expenses
-928
-886
-5%
-5%
G&A expenses
-201
-203
1%
1%
-4
11
NA
NA
-1 912
-1 871
-2%
-3%
379
297
28%
35%
-168
-180
-7%
-8%
-62
-59
4%
4%
609
536
14%
17%
Revenue
Net sales
Gross profit
Other operating expense/income
Total operating expenses
Recurring EBIT
Amortization of intangible assets
Depreciation charges
Recurring EBITDA
1 Restated for the adoption of IFRS 10 and Kremers Urban divestiture decision
EBIT: Earnings before interest and taxes
EBITDA: Earning before interests, taxes, depreciation and amortization charges
23
Net profit
€ million
FY 2014
FY 2013
Actual
(restated)1
Variance
Actual
CER
379
297
28%
35%
Impairment charges
-30
-29
-3%
-4%
Restructuring expenses
-63
-32
-95%
-96%
20
22
-9%
-12%
-34
5
NA
NA
-107
-34
>-100%
>-100%
272
263
3%
11%
-162
-142
-14%
-14%
-6
-54
89%
86%
105
67
55%
84%
94
78
21%
21%
199
145
37%
51%
Attributable to UCB shareholders
209
160
30%
43%
Attributable to non-controlling interests
-10
-15
34%
29%
Recurring EBIT
Gain on disposals
Other non-recurring income
Total non-recurring income / expenses (-)
EBIT
Net financial expenses
Income tax expenses (-) / credit
Profit from continuing operations
Profit from discontinued operations
Net profit of the Group
1 Restated for the adoption of IFRS 10 and Kremers Urban divestiture decision
EBIT: Earnings before interest and taxes
24
Core earnings per share
€ million
Net profit attributable to UCB
shareholders
FY 2014
FY 2013
Actual
(restated)1
Variance
Actual
CER
209
160
30%
43%
+ After-tax non-recurring items and
financial one-offs
109
34
>100%
>100%
- Profit (-) / loss from discontinued
operations
-94
-78
21%
21%
+ Amortization of intangibles
139
149
-7%
-8%
- Taxes on amortization of intangibles
-40
-40
0%
0%
Core net profit to UCB shareholders
322
226
43%
52%
Weighted average number of shares (mn)
191
182
5%
Core EPS
1.69
1.24
37%
1 Restated for the adoption of IFRS 10 and Kremers Urban divestiture decision
46%
25
Cash flows 2014*
€ million
* Continuing and discontinuing operations, free cash flow not affected
26
2015 and mid-term financial outlook
CVN tracking well towards peak sales target of € 3.1 billion*
2015 guidance
Revenue
rEBITDA
Core EPS
~ € 3.55 - 3.65
billion
~ € 710 – 740 million
~ € 1.90 – 2.05
Continued growth:
Cimzia®, Vimpat®,
Neupro®
• R&D expenses: strong
early and late-stage
pipeline
• Continued strict cost
management
~193.7 million shares
Mid-term guidance
• Expected R&D expense ratio of ~29% (+/- 1%)
• Recurring EBITDA of 30% => 2018
• Net debt/rEBITDA ratio of 1:1 – mid-term ambition confirmed
* By the end of this decade
Next wave of new
potential solutions
for patients
advances
Iris Löw-Friedrich, CMO
Lut, living with osteoporosis
28
Brivaracetam in POS: Filed January 2015
Epilepsy seizure reduction in treatment resistant patients
One of the largest Phase 3 programs
seen in epilepsy
Statistically significant and clinically
relevant top-line results*
Presented at AES** meeting
in Seattle, December 2014
Guoqiong, living with epilepsy
Filed with U.S. and EU authorities
(January 2015)
*
**
The most commonly reported adverse events were somnolence, dizziness, fatigue and headache. Source: UCB data on file
American Epilepsy Society
29
Phase 3 study - Primary outcomes
Statistically significant and clinically relevant top-line results*
Primary efficacy
U.S. outcome
% reduction over placebo
24
20
Reduction over Placebo (%)
P-value < 0.001
22.8
48
P-value < 0.001
23.2
16
12
50% responder rate
28
Primary Efficacy
EU Outcome
P-value < 0.001
38.9
37.8
Brivaracetam
100mg/day
Brivaracetam
200mg/day
32
24
4
8
0
0
Brivaracetam 100mg/day Brivaracetam 200mg/day
P-value < 0.001
40
16
8
50% Responder Outcome (%)
21.6
Placebo
* The most commonly reported adverse events were somnolence, dizziness, fatigue and headache.
Source: N01358 Phase 3 studyUCB data on file
30
Epratuzumab in SLE*
High unmet medical need
Moderate to severe patient population
Phase 3 studies: Embody 1 & Embody 2
Emab IV
dosing
Placebo
Emab 600 mg, weekly
Emab 1 200 mg, every other week
Week
Sabrina, living
with lupus
Primary endpoint: treatment response criteria at Week 48
according to a combined response index built primarily
around BILAG
EMBODY studies designed
to show clinically meaningful results
Phase 3 program with first results H1 2015
* Systemic Lupus Erythematosus; In-licensed from: Immunomedics
31
Romosozumab in bone loss disorders
Potential for a change of treatment paradigms
Study of naturally occurring human disorder leads to
a potential new drug therapy
healthy bone
osteoporosis bone
‘normal’
sclerosteosis
Positive Phase 2 results published in NEJM (Jan. 2014)
Manorama,
living with osteoporosis
Favorable comparison with placebo* and active
comparators, teriparatideǂ and alendronate†
Treatment with romosozumab increased total hip Bone Mineral
Density (BMD) in post-menopausal osteoporosis patients
Phase 3 programs underway in osteoporosis
First results expected H1 2016
Partner: Amgen
1 McClung, et al. N Engl J Med. DOI: 10.1056/NEJMoa1305224. http://www.nejm.org/doi/full/10.1056/NEJMoa1305224SO
* P < 0.05 vs Placebo
† P < 0.02 vs ALN
ǂ P < 0.02 vs TPTD
Potential
breakthrough passed
first decision point
Ismail Kola, CSO
Caroline, living with psoriatic arthritis
33
Transformational potential for patients and UCB
•
Transformational
potential of our
pipeline for
patients to be
recognised
externally*
•
Sustain a steady
pipeline of Phase 3
breakthrough
molecules
right target
right molecule
right indication
right patient
* eg. Listed in analysts’ most transformational drugs list
34
NewMedicines strategy for future breakthroughs
1. Deliver innovative first-inclass molecules
2. Increase success rates (and
“kill early”)
3. Implement super network
and open innovation model
4. Enhance scientific excellence
5. Increase efficiency
6. Strategic asset partnering
35
Paradigm to pick winners and kill early
Potential breakthrough to pass decision points
TEST THE THEORY - LEARN
CANDIDATE
APPROVAL
FIH*–
including target
engagement
biomarker
* FIH – first in human; **POC – proof of concept
CONFIRM THE THEORY
POC** at Ph 2b
– robust
POC** -light in man
register-able
– endpoints
endpoint
for internal decision
making
APPROVAL
AND
LAUNCH
36
UCB's early development pipeline
Pipeline filled with new molecular entities, post 1. decision point
Phase 1
UCB4940 (IL17AF)
psoriatic arthritis
Phase 2
Phase 2 results: H2 2015
UCB0942 (PPSI)
highly drug resistant epilepsy
Phase 2 start: H2 2015
UCB5857 (PI3K Delta inhibitor)
immune-inflammatory diseases
Phase 2 start: H2 2015
dapirolizumab pegol (CD40L antibody)*
systemic lupus erythematosus
Phase 2 start: 2016
UCB7665
immunological diseases
Phase 3
neurology
immunology
*Partner: Biogen Idec
Conclusion
Jean-Christophe Tellier, CEO
Bernd, living with rheumatoid
arthritis & ankylosing spondylitis
38
UCB: The patient preferred biopharma
2014: Core medicines grow by 24% while next wave of new
potential solutions for patients advances
Patients
Shareholder
value
Patient
value
Solutions
Sciences
Appendix
Susanne, living with axial spondyloarthritis
40
FY 2014 net sales
Core
medicines
€ 2 938 million (+5%; +6% CER)
Mature products
Total core products sales
€ 1 468 million (+24%)
Total mature products sales
€ 1 470 million (-9%)
FY 2013 net sales
Keppra® net sales include Keppra® XR and AG net sales
Zyrtec® net sales include Zyrtec-D® and Cirrus® net sale
FY 2014 net sales
41
Debt maturity schedule
31 December 2014
(€ million)
807
300
509
375
305
375
117
250
500
167
206
185
350
250
176
75
Liquid
assets
2015
2016
2017
2018
2019
2020
2021
2022
Belgian Commercial Paper
Belgian retail bond
Institutional eurobond
Perpetual bond
Other loans
EIB loan
1 Perpetual bond with first call date in March 2016, recognized as equity on UCB’s balance sheet
2023
beyond
42
Workforce distribution
Total headcount @ 31 Dec 2014: 8 486 employees
Employees by function
Employees by region
43
R&D milestones
>
2015
>
2016
2017
Vimpat®
brivaracetam
UCB0942
romosozumab
epilepsy POS –
adjunctive therapy
U.S. & EU filing
Highly drug
resistant epilepsy
Phase 2 start
osteoporosis in postmenopausal women
Phase 3 results
osteoporosis in men
Phase 3 results
epilepsy POS –
ped. adj. therapy
Phase 3 results
Vimpat®
Vimpat®
PGTCS –
adjunctive therapy
Phase 3 start
epilepsy POS
monotherapy EU
Phase 3 results
Cimzia®
Cimzia®
Cimzia®
C-Early™
Exxelerate™
Phase 3 results
Phase 3 results
epratuzumab
UCB4940
Cimzia®
SLE
Phase 3 results
psoriatic arthritis
Phase 2 results
juvenile IA
Phase 3 results
Cimzia®
UCB5857
dapirolizumab
pegol
psoriasis
Phase 3 start
Immuninflammatory
Phase 2 start
romosozumab
psoriasis
Phase 3 results
SLE
Phase 2 start
neurology
immunology
IA: Idiopathic Arthritis
SLE: Systemic Lupus Erythematosus
POS: Partial-Onset Seizures
PGTCS: Primary Generalized Tonic-Clonic Seizures
44
R&D milestones
2014
>
>
2015
>
2016
Vimpat®
POS – mono
USA
approval
UCB5857
immunology
phase 1 results
brivaracetam
UCB0942
romosozumab
epilepsy POS –
adjunctive therapy
U.S. & EU filing
Highly drug
resistant epilepsy
Phase 2 start
osteoporosis in postmenopausal women
Phase 3 results
osteoporosis in men
Phase 3 results
Vimpat®
Vimpat®
PGTCS –
adjunctive therapy
Phase 3 start
epilepsy POS
monotherapy EU
Phase 3 results
Cimzia®
Cimzia®
C-Early™
Exxelerate™
Phase 3 results
epratuzumab
UCB4940
Cimzia®
SLE
Phase 3 results
psoriatic arthritis
Phase 2 results
juvenile IA
Phase 3 results
Cimzia®
UCB5857
dapirolizumab
pegol
CDP7657
SLE
phase 1b results
brivaracetam
epilepsy POS adj. therapy phase 3 results
psoriasis
Phase 3 start
Immuninflammatory
Phase 2 start
Phase 3 results
romosozumab
SLE
Phase 2 start
Vimpat®
POS –
Asia
Phase 3 results
IA: Idiopathic Arthritis
SLE: Systemic Lupus Erythematosus
neurology
immunology
POS: Partial-Onset Seizures
PGTCS: Primary Generalized Tonic-Clonic Seizures
45
UCB's development pipeline
Pipeline filled with new molecular entities
Phase 1
Phase 2
Phase 3
brivaracetam
epilepsy POS1 / adj. therapy
Filed: early 2015
epratuzumab
systemic lupus erythematosus
Phase 3 results: H1 2015
romosozumab
osteoporosis - postmenopausal women
Phase 3 results: H1 2016
romosozumab
osteoporosis - men
Phase 3 results: H2 2016
UCB4940 (IL17AF)
psoriatic arthritis
(Partner: Immunomedics)
(Partner: Amgen)
(Partner: Amgen)
Phase 2 results: H2 2015
UCB5857 (PI3K Delta inhibitor)
immunological diseases
Phase 2 start: H2 2015
dapirolizumab pegol (CD40L antibody)
systemic lupus erythematosus
Phase 2 start: 2016
(Partner: Biogen Idec)
UCB0942 (PPSI)
highly drug resistant epilepsy
Phase 2 start: H2 2015
UCB7665
immunological diseases
1 Partial onset seizures
Filing
46
Cimzia® offers 2 unique solutions for the U.S. market
Lyophilized formulation and prefilled syringe
Lyophilized formulation accounts for approx.
20% of U.S. Cimzia® sales measured in IMS
dollarized sales
Consistent and continued growth of prefilled
syringe as measured in IMS dollarized sales
+17%
+36%
+25%
+27%
$55
$188
$47
$35
$38
H1 2012
H2 2012
H1 2013
$283
+15%
$70
+23%
$331
+10%
+17%
+10%
+10%
$95
$206
$226
$163
H2 2013
IMS data is NSP ending rolling 6 month, ending December 2014
H1 2014
H2 2014
H1 2012
H2 2012
H1 2013
H2 2013
H1 2014
H2 2014
47
Shareholder structure
Stable shareholder base with free-float of 64%
Total number of shares: 194.5 million
Weighted average shares outstanding in 2014: 191 million
“Free float” investors by region
Source: Shareholder identification analysis (November 2014), 2013 and 2014 notifications and UCB underlying ownership analysis
48
Your UCB Investor Relations team
‫ן‬
‫ן‬
‫ן‬
Antje Witte, Vice President Investor Relations
• Phone: +32 2 559 9414
• E-mail: [email protected]
Isabelle Ghellynck, Investor Relations Manager
• Phone: +32 2 559 9588
• E-mail: [email protected]
Nathalie Deldime, Investor Relations Events Manager
• Phone: +32 2 559 9291
• E-mail: [email protected]